Dihydrotachysterol, vials 0.1%, 10ml

Composition

Active ingredient:  

dihydrotachysterol – 1 mg;

Auxiliary substances:

refined deodorized sunflower oil or refined deodorized soybean oil up to 1 ml

Pharmacological action

Dihydrotachysterol is a drug that regulates metabolic processes. Regulator of calcium and phosphorus metabolism. Dihydrotachysterol increases the absorption of calcium in the intestines, thereby increasing its level in the blood.

The drug also increases the excretion of inorganic phosphorus by the kidneys. Dihydrotachysterol can be used for a long time without developing overdose or tolerance effects.

The effect of the drug is faster at the beginning of treatment and less prolonged after the end of the course than that of vitamin D, which reduces the risk of accumulation of the drug in the body and the development of hypercalcemia.

Dihydrotachysterol can be toxic at a dose of about 25 mg per day, which is expressed by symptoms of hypercalcemia. It does not cause addictive phenomena.

Indications

Hypoparathyroidism (idiopathic and postoperative), pseudohypoparathyroidism, tetany (muscle cramps caused by hypocalcemia), bone diseases caused by vitamin D deficiency.

Contraindications

Hypercalcemia, hypervitaminosis D, hypersensitivity to dihydrotachysterol and other vitamin D preparations.

Side effects

From the digestive system:  anorexia, nausea, vomiting, diarrhea; when used in high doses – biliary dyskinesia.

From the cardiovascular system:  palpitations; rarely-cardiac arrhythmias.

From the side of metabolism:  thirst, calcification of tissues.

From the urinary system:  with long – term therapy-impaired renal function.

Other services:  pallor of the skin, headache.

Interaction

When dihydrotachysterol is taken simultaneously with vitamin D, as well as with medications and dietary supplements containing calcium, hypercalcemia may develop.

Hypercalcemia may occur when dihydrotachysterol is co-administered with thiazide diuretics and rifampicin. Dihydrotachysterol enhances the action of cardiac glycosides and calcium antagonists. When taking cardiac glycosides or calcium antagonists simultaneously with dihydrotachysterol, it is possible to reduce the dose of the latter.

Barbiturates (phenobarbital), antiepileptic drugs [phenytoin (diphenine), carbamazepine (finlepsin), primidone (hexamidine)anion exchange resins (colestyramine, colestipol) and vaseline oil weaken the pharmacological effect of dihydrotachysterol.

If thyroxine treatment is performed simultaneously with dihydrotachysterol, then hypercalcemia may develop after its withdrawal.

How to take, course of use and dosage

When taken orally, the daily dose is 0.25-1.5 mg.

The frequency of application depends on the indications and concentrations of calcium in the blood and urine.

Form of production

Drops for oral use

Storage conditions

In a dark place, at a temperature of 0-15 °C.

Shelf

life 2.5 years

Active ingredient

Dihydrotachysterol

Conditions of release from pharmacies

By prescription

Dosage form

solution for oral use

Indications

Tuberculosis, Cancer, Calcium Deficiency